UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 4.346

Sortiert nach

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy

Molecular pharmaceutics, 2018-10, Vol.15 (10), p.4426-4433

2018

Volltextzugriff (PDF)

847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A945-A945

2023

Volltextzugriff (PDF)

Abstract 1853: A novel anti-CTLA-4 checkpoint inhibitor prodrug to address on-target off-tumor toxicity for cancer immunotherapy

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1853-1853

2021

Volltextzugriff (PDF)

Abstract 4538: A safe and potent agonist ADG106 targeting a unique epitope of CD137 with novel mechanism of actions

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4538-4538

2020

Volltextzugriff (PDF)

ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass

Blood, 2021-11, Vol.138 (Supplement 1), p.3342-3342

2021

Volltextzugriff (PDF)

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety

Blood, 2021-11, Vol.138 (Supplement 1), p.1204-1204

2021

Volltextzugriff (PDF)

Abstract A082: A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A082-A082

2019

Volltextzugriff (PDF)

Development of a unique anti-CD137 therapeutic antibody: Efficacy and safety profiles in mono and combination therapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23079-e23079

2017

Volltextzugriff (PDF)

Abstract 2930: ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2930-2930

2023

Volltextzugriff (PDF)

Abstract 4257: ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.4257-4257

2022

Volltextzugriff (PDF)

Abstract 2868: ADG206, an anti-CD137 agonistic POWERbody࣪ with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single and combinational cancer immunotherapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2868-2868

2022

Volltextzugriff (PDF)

Abstract 2869: ADG138, a novel HER2×CD3 POWERbody™ integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2869-2869

2022

Volltextzugriff (PDF)

Abstract 2888: Tumor-targeted CD28 bispecific POWERbody࣪ for safe and synergistic T cell-mediated immunotherapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2888-2888

2022

Volltextzugriff (PDF)

Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T reg depletion and soft ligand blocking in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e17601-e17601

2022

Volltextzugriff (PDF)

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14518-e14518

2023

Volltextzugriff (PDF)

A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3105-3105

2020

Volltextzugriff (PDF)

Dogs' Eavesdropping from people's reactions in third party interactions

PloS one, 2013-11, Vol.8 (11), p.e79198-e79198

2013

Volltextzugriff (PDF)

Antonio : 1. Preis des vierten Kurzgeschichten-Wettbewerbes SFD

Am häuslichen Herd : schweizerische illustrierte Monatsschrift, 1959-09, Vol.62 (24), p.466

Bois, Felix du

1959

Volltextzugriff (PDF)

TRAITS MORPHOPEDOLOGIQUES DUNE PENEPLAINE DE SAVANE ARBOREE A BROBO AU CENTRE DE LA COTE DIVOIRE

International journal of advanced research (Indore), 2021-10, Vol.9 (10), p.657-662

2021

Volltextzugriff (PDF)

PETROGRAPHY AND HYDROTHERMAL ALTERATION OF ULTRAMAFIC BED-ROCKS OF SOUTH SIPILOU: IMPLICATION IN THE LATERITIC NICKEL MINERALIZATION (DEPARTMENT OF SIPILOU, WESTERN IVORY COAST)

International journal of advanced research (Indore), 2022-10, Vol.10 (10), p.1050-1061

2022

Volltextzugriff (PDF)

CARTOGRAPHIE DES ZONES A RISQUE DINONDATION PAR DEBORDEMENT DES COURS DEAU DANS LA REGION SEMI-MONTAGNEUSE DE MAN : APPROCHE PAR TELEDETECTION ET ANALYSE MULTICRITERE

International journal of advanced research (Indore), 2023-08, Vol.11 (8), p.116-134

2023

Volltextzugriff (PDF)

APPORT DE LA GEOMATIQUE ALA DELIMITATION DES PERIMETRES DE PROTECTION AUTOUR DE LA PRISE DEAUPOUR LALIMENTATION EN EAU POTABLE SUR LA RIVIERE ME A KONGOFON (SUD EST DE LA COTE DIVOIRE)

International journal of advanced research (Indore), 2023-07, Vol.11 (7), p.10-29

2023

Volltextzugriff (PDF)

APPORT DE LA GEOMATIQUE ALA DELIMITATION DES PERIMETRES DE PROTECTION AUTOUR DE LA PRISE DEAUPOUR LALIMENTATION EN EAU POTABLE SUR LA RIVIERE ME A KONGOFON (SUD-EST DE LA COTE DIVOIRE)

International journal of advanced research (Indore), 2023-06, Vol.11 (6), p.403-421

2023

Volltextzugriff (PDF)

OUVRAGES DE CAPTAGE DEAU ET PERIMETRES DE PROTECTION: CAS DES NOUVEAUX CHAMPS CAPTANTS DE DJIBI ET DE NIANGON NORD II A ABIDJAN (COTE DIVOIRE)

International journal of advanced research (Indore), 2022-11, Vol.10 (11), p.561-579

2022

Volltextzugriff (PDF)

Zur Symptomatologie der Occipitaltumoren

Bois-Reymond, Felix du

1917

Volltextzugriff (PDF)

1 – 25 von 4.346

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.927)
Mit Volltextzugriff
(3.750)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy

847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

Abstract 1853: A novel anti-CTLA-4 checkpoint inhibitor prodrug to address on-target off-tumor toxicity for cancer immunotherapy

Abstract 4538: A safe and potent agonist ADG106 targeting a unique epitope of CD137 with novel mechanism of actions

ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety

Abstract A082: A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma

Development of a unique anti-CD137 therapeutic antibody: Efficacy and safety profiles in mono and combination therapy

Abstract 2930: ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment

Abstract 4257: ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities

Abstract 2868: ADG206, an anti-CD137 agonistic POWERbody࣪ with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single and combinational cancer immunotherapy

Abstract 2869: ADG138, a novel HER2×CD3 POWERbody™ integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors

Abstract 2888: Tumor-targeted CD28 bispecific POWERbody࣪ for safe and synergistic T cell-mediated immunotherapy

Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T reg depletion and soft ligand blocking in patients with advanced solid tumors

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling

A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma

Dogs' Eavesdropping from people's reactions in third party interactions

Antonio : 1. Preis des vierten Kurzgeschichten-Wettbewerbes SFD

TRAITS MORPHOPEDOLOGIQUES DUNE PENEPLAINE DE SAVANE ARBOREE A BROBO AU CENTRE DE LA COTE DIVOIRE

PETROGRAPHY AND HYDROTHERMAL ALTERATION OF ULTRAMAFIC BED-ROCKS OF SOUTH SIPILOU: IMPLICATION IN THE LATERITIC NICKEL MINERALIZATION (DEPARTMENT OF SIPILOU, WESTERN IVORY COAST)

CARTOGRAPHIE DES ZONES A RISQUE DINONDATION PAR DEBORDEMENT DES COURS DEAU DANS LA REGION SEMI-MONTAGNEUSE DE MAN : APPROCHE PAR TELEDETECTION ET ANALYSE MULTICRITERE

APPORT DE LA GEOMATIQUE ALA DELIMITATION DES PERIMETRES DE PROTECTION AUTOUR DE LA PRISE DEAUPOUR LALIMENTATION EN EAU POTABLE SUR LA RIVIERE ME A KONGOFON (SUD EST DE LA COTE DIVOIRE)

APPORT DE LA GEOMATIQUE ALA DELIMITATION DES PERIMETRES DE PROTECTION AUTOUR DE LA PRISE DEAUPOUR LALIMENTATION EN EAU POTABLE SUR LA RIVIERE ME A KONGOFON (SUD-EST DE LA COTE DIVOIRE)

OUVRAGES DE CAPTAGE DEAU ET PERIMETRES DE PROTECTION: CAS DES NOUVEAUX CHAMPS CAPTANTS DE DJIBI ET DE NIANGON NORD II A ABIDJAN (COTE DIVOIRE)

Zur Symptomatologie der Occipitaltumoren

Suchergebnisse filtern